top of page
Precision Neoepitope Discovery
Get Started
Partnering with ImmunoEdge means accelerating the development of personalized and scalable therapies, addressing critical gaps in precision oncology.
At ImmunoEdge, we are open to collaborate with biotech innovators, research institutions, and industry leaders to drive breakthroughs in cancer immunotherapy. If you’re interested in advancing precision immunopeptidomics, let’s explore synergies—whether through partnerships, applied expertise, or strategic insights.
Mogjib Salek, PhD
Founder, ImmunoEdge
Heidelberg, Germany
bottom of page